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Abstract
Effective prevention, or treatment, of invasive fungal
infection in the neutropenic patient has hitherto been
unsatisfactory because of either an inadequate anti-fun-
gal spectrum of the agent or important toxicity. Itracona-
zole is effective against a broad spectrum of the opportu-
nistic pathogens seen in Europe and North America.
Prior problems with absorption, e.g. in the marrow trans-
plant recipient, have been overcome with the introduc-
tion of an oral solution and an i.v. preparation. The delib-
erations of an expert meeting held in June, 1998 include
recommendations on which patient requires one of
these new preparations based on clinical trials, the dose
and route. Important drug interactions are also detailed.
This is an expert report of a meeting held in London on 20 June 1998
on itraconazole. The meeting was supported by an unrestricted edu-
cational grant from Janssen-Pharmaceutica and Janssen Research
Foundation, Beerse, Belgium.
Introduction
Systemic fungal infection is an increasing problem in
patients receiving immunosuppressive chemotherapy for
haematological malignancies and in bone marrow trans-
plant recipients. Contributory factors include the use of
broad-spectrum antibiotics, corticosteroids, central ve-
nous catheters, profoundly immunosuppressive chemo-
therapy, intensive irradiation protocols and mismatched
or unrelated donor transplants, despite the increasing use
of rooms with high-efficiency particulate air filtration.
Previously, most infections were by Candida species.
Although infection by Candida albicans is decreasing, the
incidence of non-C. albicans isolates is increasing [1]. In
Europe, Aspergillus species are now the most frequently
identified invasive pathogens. Mucorales are seen occa-
sionally and any of a wide range of emerging fungi, such as
Fusarium, Scedosporium and Trichosporon, may be in-
volved [2, 3]. Broad-spectrum antifungal therapy is there-
fore required.
Many fungal infections are diagnosed only at autopsy
[4] because current diagnostic tools are largely inade-
quate; as a result, prophylaxis and empirical therapy play
a key role in patient management. The agents used most
frequently are amphotericin B (the treatment of choice for
many years), fluconazole and itraconazole.
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Amphotericin B has a broad spectrum of activity (in-
cluding against Candida and Aspergillus species) [5], but
conventional formulations are associated with acute toxic
reactions and nephrotoxicity [2]. New lipid-based prepa-
rations of amphotericin B are now available; each is likely
to be at least as effective as and less nephrotoxic than the
conventional formulations [6, 7], but optimum therapeut-
ic dosages require clarification.
Fluconazole is used extensively [8–12], particularly as
prophylaxis, but it has a limited spectrum of activity (it is
ineffective against Aspergillus and some non-C. albicans
species, such as Candida krusei) and the emergence of
drug resistance has been reported [13–16].
Itraconazole is active against a wide range of dermato-
phytes, yeasts and fungi (including Candida and Aspergil-
lus species) [17], but the standard capsule formulation is
less suitable for use in some patients because absorption
from the capsules is impaired in patients with gastrointes-
tinal epithelial damage [18]; in addition, because absorp-
tion depends on gastric acidity, the capsules must be tak-
en with food to achieve optimum bioavailability; they
may therefore be absorbed suboptimally by patients with
restricted oral food intake [19–21].
The use of hydroxypropyl-ß-cyclodextrin has enabled
the development of two new itraconazole formulations
(an oral solution and an intravenous preparation), which
provide higher, more consistent plasma concentrations of
itraconazole than the capsule formulation does [22–27]
and should facilitate the effective use of this agent in a
wider range of patients.
A meeting was held in London, UK, on 20 June 1998,
to discuss the use of the itraconazole oral solution and
intravenous formulations in neutropenic or otherwise im-
munosuppressed patients. Specific questions were ad-
dressed in a round-table discussion and pharmacokinetic
and efficacy data were presented to facilitate informed
debate. This publication is a summary of the practical rec-
ommendations made at the meeting regarding the use of
the new itraconazole formulations in this patient popula-
tion.
Prophylaxis
Which Patients Require Prophylaxis?
Prophylaxis with itraconazole was recommended for
patients who are expected to have neutropenia (neutro-
phil count 0.1–0.5 ! 109/l) for at least 2 weeks or pro-
found neutropenia (neutrophil count !0.1 ! 109/l) for
more than 1 week. Prophylaxis may not be required for
patients receiving autologous peripheral stem cell trans-
plants because they have a relatively short period of
neutropenia (compared with bone marrow transplant
recipients).
The incidence of systemic fungal infection depends not
only on the severity of neutropenia but also on the
underlying disease. Lower rates of infection (4–5%) occur
in patients undergoing autologous bone marrow trans-
plantation, especially those with solid tumours receiving a
colony-stimulating factor [28]; intermediate rates (8%)
are documented in patients with acute leukaemia [11, 12]
and higher rates (16–18%) are reported in patients un-
dergoing allogeneic bone marrow transplantation for hae-
matological malignancies [9,10]. The risk of Aspergillus
infection in allogeneic bone marrow transplant recipients
is higher if the patient is older, has acute myelogenous leu-
kaemia beyond first remission, has graft-versus-host dis-
ease treated with high-dose steroids or is not treated in a
laminar airflow room with high-efficiency particulate air
filtration or when unrelated donors are used. In addition,
the risk of Aspergillus infection is higher in patients with
relapsing or progressive acute myelogenous leukaemia or
other haematological malignancies if they receive high
doses of gut-damaging chemotherapy, fludarabine or
powerful immunosuppressive agents such as steroids.
Have the New Itraconazole Formulations Been
Evaluated in the Prophylactic Setting?
The itraconazole oral solution (5 mg/kg/day) has been
evaluated as prophylaxis during neutropenic episodes in
three major studies; results are summarized in table 1.
Study 1 was a double-blind, placebo-controlled trial with
blinded review and standard antibiotics (n = 405) [29].
Prophylaxis was started at the same time as chemothera-
py. Patients undergoing allogeneic bone marrow trans-
plantation or receiving high-dose cytosine arabinoside
were excluded. Study 2 and study 3 used similar patient
populations, but allogeneic bone marrow transplant recip-
ients were included in study 2. Study 2 was an open, ran-
domized comparison with fluconazole 100 mg/day (n =
445) [30]. Study 3 was a double-blind, double-dummy
comparison with oral amphotericin B 2 g/day (n = 557),
with blinded review and an interim analysis [31]; this trial
was stopped prematurely because the anticipated inci-
dence of aspergillosis was not reached in either arm.
Fewer fungal infections occurred in the itraconazole
groups than in the comparison groups in all three studies
(significant difference vs. placebo in study 1). Conse-
quently, the use of intravenous amphotericin B therapy
was also lower in the itraconazole group in all three stud-
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48*, a 68*, a 67 82 93 103
Deep aspergillosis 4 1 0 4 5 9
Use of i.v. amphotericin B 43** 59** 39* 58* 90 102
Death with proven deep fungal infection 1 5 0* 4* 1 5
*p ^  0.05 (statistical significance); 0.05 ! **p ^  0.1 (statistical trend). n = Number of patients.
a Proven deep fungal infections (itraconazole n = 5, placebo n = 9) plus suspected deep fungal infections requiring empirical amphotericin B
(itraconazole n = 43, placebo n = 59).
ies (significant difference vs. fluconazole in study 2; trend
towards significant difference vs. placebo in study 1). This
observation is of particular clinical relevance because of
the risk of severe nephrotoxicity with intravenous ampho-
tericin B. The incidence of deep aspergillosis was consis-
tently low across the studies; indeed, the overall incidence
of mould infection was low in all three studies, which may
explain the lack of statistical difference between groups.
Additionally, in study 1, significantly lower incidences of
candidaemia (itraconazole n = 1, placebo n = 8; p ! 0.05)
and fewer deaths related to Candida infection (itracona-
zole n = 0, placebo n = 4) were seen in the itraconazole
group than in the placebo group. Fewer deaths with prov-
en deep fungal infection occurred in the itraconazole
groups in all three studies (table 1).
The itraconazole intravenous formulation is currently
under evaluation as prophylaxis for allogeneic bone mar-
row transplant recipients.
Which Itraconazole Formulations Should Be Used for
Prophylaxis?
The itraconazole oral solution was considered to be
appropriate for prophylaxis, starting from day 1 of che-
motherapy. One week of the intravenous formulation and
the oral solution thereafter was considered to be an appro-
priate prophylactic regimen for high-risk patients, such as
allogeneic bone marrow transplant recipients. The intra-
venous formulation was considered to be appropriate for
patients unable to take oral medication (i.e. those with
chemotherapy-induced, severe, oral and intestinal muco-
sitis). Further information is needed to assess the poten-
tial impact of interactions between azole antifungals and
chemotherapeutic agents on multidrug resistance and the
timing of prophylaxis.
Which Patients May Require Long-Term Prophylaxis?
Patients receiving corticosteroids, patients undergoing
mismatched bone marrow transplantation, patients with
graft-versus-host disease, patients who have received pro-
foundly immunosuppressive chemotherapy (such as com-
binations containing fludarabine) or durable semi-inten-
sive chemotherapy for acute lymphoblastic leukaemia
and patients undergoing another course of myeloablative
chemotherapy who have had a previous invasive fungal
infection (such as aspergillosis) were considered to require
long-term prophylaxis beyond the period of neutropenia.
What Factors May Affect the Long-Term
Administration of the Itraconazole Oral Solution?
Some patients receiving the itraconazole oral solution
may experience cyclodextrin-associated diarrhoea, which
is usually well tolerated; however, if the diarrhoea be-
comes problematic and gastrointestinal absorption is un-
impaired, a switch from the oral solution during neutro-
penia to capsules after neutrophils have recovered was
proposed. (Neutrophils are used as a marker of mucosal
repair, except in graft-versus-host disease affecting the
gastrointestinal tract.) Intermittent monitoring of the
plasma concentration of itraconazole is advised if the cap-
sule formulation is used in the long term.
Empirical and Definitive Therapy
Have the New Itraconazole Formulations Been Evaluated
in the Treatment Setting?
The efficacy of the itraconazole oral solution in oral
candidiasis [32–34] and oesophageal candidiasis [35] has
been compared with that of fluconazole in HIV-positive
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individuals. In all four studies, the response rates were
equivalent. In most cases, the causative organism was
C. albicans.
The itraconazole intravenous formulation is under
evaluation as definitive treatment for aspergillosis and
candidiasis and as empirical therapy for fever that is unre-
sponsive to antibiotics in patients with persistent neutro-
penia.
Which Itraconazole Formulations Should Be Used for
Treatment?
One week of the itraconazole intravenous formulation
and the oral solution thereafter were considered to be an
acceptable regimen for empirical treatment.
An earlier switch to the itraconazole oral solution was
also considered to be a viable option, given that an ade-
quate plasma concentration of itraconazole is achieved
after 2 days of treatment with the intravenous formula-
tion [27]. Because the two new formulations have equiva-
lent spectra of activity and bioavailability, only a patient’s
inability to take oral medication should delay a switch
from intravenous itraconazole to the oral solution.
A longer overall period of treatment was considered to
be required for aspergillosis than for candidiasis (non-C.
albicans) but a precise duration could not be agreed.
Treatment for 1 week beyond resolution of all diagnostic
features of infection (fever, computed tomography scan)
was considered the minimum requirement in patients
whose neutrophils have recovered.
For patients who do not respond to itraconazole, a
switch to amphotericin B was recommended (the choice
of amphotericin B formulation should be made according
to local practice and taking specific indication, renal func-
tion and concomitant use of other nephrotoxic drugs into
consideration); no data are currently available on switch-
ing back to intravenous itraconazole in this setting.
Have the New Itraconazole Formulations Been
Evaluated in Patients with Fluconazole-Resistant
Infections?
At present, no data are available for neutropenic pa-
tients, but the itraconazole oral solution has been evaluat-
ed in three open trials in HIV-positive individuals with
fluconazole-resistant or fluconazole-refractory oropha-
ryngeal candidiasis [36–38]. Responses ranged from 60 to
80%. Causative agents were C. albicans (75.4% of cases),
Candida glabrata (17.4%) and C. krusei (5.9%). Response
was achieved in 23 of 25 patients with a fluconazole-resis-
tant C. glabrata infection.
General Considerations
What Is the Target Plasma Concentration of
Itraconazole?
Tentative interpretive minimal inhibitory concentra-
tion breakpoints for itraconazole have been established
for mucosal candidal infections: susceptible 100–250 ng/
ml, susceptible dependent on dose 250–500 ng/ml, and
resistant 61,000 ng/ml [39]. A plasma concentration of
itraconazole of at least 250–500 ng/ml was therefore con-
sidered to be desirable.
Early pharmacokinetic data from autologous bone
marrow transplant recipients show that use of the itracon-
azole oral solution 5 mg/kg once daily during remission-
induction treatment produced serum concentrations of
itraconazole that reached (and exceeded) 500 ng/ml from
day 8 onwards [22]. When itraconazole was given prophy-
lactically, 86–100% of patients reached adequate levels
after 12 days [29].
In patients who received a loading dose of intravenous
itraconazole 200 mg twice daily for 2 days followed by
200 mg once daily from day 3 to day 7, steady-state plas-
ma concentrations of itraconazole of 250 ng/ml were
achieved by day 1 and 500 ng/ml by day 2. In addition, a
plasma concentration of at least 500 ng/ml was main-
tained after a switch to the oral solution 200 mg twice dai-
ly at day 7 [27].
Both new itraconazole formulations therefore rapidly
produce target plasma concentrations of the drug. (Itra-
conazole concentrations were obtained by high-perfor-
mance liquid chromatography.)
Is Monitoring Required?
For both the oral solution and the intravenous formu-
lation of itraconazole, monitoring of the plasma drug con-
centration was considered to be unnecessary (given the
reliable pharmacokinetic profiles) [40] and impractical
(given the short anticipated duration of neutropenia).
Monitoring plasma itraconazole concentrations may be
useful when the oral solution or the intravenous formula-
tion is used for treatment of documented infection.
How Should the Itraconazole Oral Solution Be Taken
to Achieve Optimum Bioavailability?
In healthy volunteers, the relative bioavailability of the
itraconazole oral solution exceeds that of the capsule for-
mulation when both are taken with food [31]. In addition,
unlike the capsule formulation, bioavailability is in-
creased with the oral solution under fasting conditions
(fig. 1) [41, 42].
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Fig. 1. Itraconazole capsules and oral solution in healthy volunteers:































Can the New Itraconazole Formulations Be Used in
Patients with Impaired Gastrointestinal Absorption?
The itraconazole oral solution was considered to be
appropriate for allogeneic bone marrow transplant recipi-
ents with impaired gastrointestinal absorption, including
that caused by severe graft-versus-host disease of the
intestine. However, the intravenous formulation was rec-
ommended for patients with severe mucositis.
What Other Factors Might Influence the Choice of
Itraconazole Formulation?
If a patient is unconscious or intubated, oral adminis-
tration of any antifungal agent is not always appropriate.
The recommendation was made to switch patients to
the itraconazole intravenous formulation if they experi-
ence unacceptable gastrointestinal upset with the oral
solution and do not require long-term treatment. A trial is
in progress in the UK to examine the pharmacokinetics of
switching from the itraconazole oral solution to the intra-
venous formulation, to determine whether a loading dose
is still appropriate in this setting.
Which Drugs Should Not Be Given with Itraconazole
or Require Special Precautions?
The following drugs should not be given concurrently
with itraconazole: terfenadine, astemizole, cisapride, pi-
mozide, HMG-CoA reductase inhibitors such as simva-
statin and lovastatin, oral midazolam or triazolam.
Inhibition of cytochrome P450 by itraconazole may
lead to reduced clearance of oral anticoagulants, digoxin,
cyclosporin A, systemic methylprednisolone, vinca alka-
loids [43, 44], dihydropyridine calcium channel blockers,
quinidine, intravenous midazolam, clarithromycin, phe-
nytoin, tacrolimus and busulphan [45]. These drugs re-
quire monitoring and may require dose reductions. Other
drugs may increase the elimination of itraconazole (rifam-
picin, carbamazepine and isoniazid) and may lead to sub-
therapeutic blood levels of itraconazole.
Which Drugs Are Not Affected by Itraconazole?
In vitro studies have shown that no interactions on plas-
ma protein binding occur between itraconazole and imip-
ramine, propranolol, diazepam, cimetidine, indometha-
cin, tolbutamide or sulphamethazine.
No interaction between itraconazole and zidovudine
or omeprazole and no inducing effects of itraconazole on
the metabolism of ethinyloestradiol and norethisterone
have been observed.
How Will the New Itraconazole Formulations
Contribute to the Management of Systemic
Fungal Infections?
The new formulations of itraconazole are expected to
play an important role in the management of systemic
fungal infection for several reasons. First, they provide
high, consistent plasma concentrations of itraconazole.
With the intravenous formulation, adequate plasma con-
centrations of itraconazole are achieved rapidly (in 2
days). With the oral solution, optimum bioavailability is
achieved under fasting conditions (whereas the capsule
formulation must be taken with food). For both the oral
solution and the intravenous formulation, monitoring of
the plasma concentration of itraconazole is unnecessary.
Furthermore, allogeneic bone marrow transplant recipi-
ents with impaired gastrointestinal absorption caused by
severe graft-versus-host disease can still receive the itra-
conazole oral solution, whereas patients who cannot swal-
low or tolerate the oral solution can receive itraconazole
by intravenous infusion.
Overall, therefore, the new itraconazole formulations
should provide clinicians with greater flexibility in the
management of systemic fungal infection in neutropenic
haematological patients and they are expected to reduce
the use of intravenous amphotericin B, with resultant
patient benefit.
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